Premium
Efficacy and safety of midazolam and vesparax in treatment of sleep disorders.
Author(s) -
Fischbach R
Publication year - 1983
Publication title -
british journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.216
H-Index - 146
eISSN - 1365-2125
pISSN - 0306-5251
DOI - 10.1111/j.1365-2125.1983.tb02290.x
Subject(s) - midazolam , hydroxyzine , placebo , medicine , anesthesia , double blind , double blind study , benzodiazepine , sedation , alternative medicine , pathology , receptor
In a double‐blind parallel study in which a placebo phase preceded and followed the double‐blind verum phase, midazolam 15 mg and Vesparax (150 mg secobarbital, 50 mg brallobarbital, 50 mg hydroxyzine) were administered to 30 female patients aged 20‐76 years, suffering from insomnia secondary to neuromuscular disease. Both products were shown to be efficient hypnotics maintaining a constant level of effect. Midazolam proved to be better tolerated and, in contrast to Vesparax, did not cause hangover, nor did rebound phenomena ensue after its withdrawal.